Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Cervical Cancer

Free Subscription Articles published in Int J Gynecol Cancer Retrieve available abstracts of 208 articles: HTML format

Single Articles

January 2026
1. CIBULA D, Mburu A, Planchamp F, Zapardiel I, et al
   European Society of Gynaecological Oncology resource-stratified guidelines for the management of patients with cervical cancer.
   Int J Gynecol Cancer. 2026;36:102747.
   PubMed     Abstract available
   
   
   
2. LEE SS, Banson K, Koduru H, Berger AA, et al
   Factors associated with treatment delay for cervical cancer patients treated with definitive chemoradiation and brachytherapy.
   Int J Gynecol Cancer. 2026;36:102774.
   PubMed     Abstract available
   
   
   
3. TORIGOE R, Dennen C, Mayadev J, Makale MT, et al
   Current challenges in the assessment and management of radiotherapy-induced vaginal stenosis.
   Int J Gynecol Cancer. 2026;36:102801.
   PubMed     Abstract available
   
   
   
4. MARUCCI DA SILVA GF, Pilger TL, Candido Dos Reis FJ
   Incidence of urologic co-morbidities after abdominal radical hysterectomy: a systematic review of clinical trials.
   Int J Gynecol Cancer. 2026;36:102722.
   PubMed     Abstract available
   
   
   
5. WILLIAMS G, Bindra A, Fink D, Weintraub MR, et al
   Survival in human papillomavirus and non-human papillomavirus-associated invasive endocervical adenocarcinoma: outcomes in a large, integrated healthcare system.
   Int J Gynecol Cancer. 2026;36:102683.
   PubMed     Abstract available
   
   
   December 2025
6. CIANCIA M, Mascilini F, Moro F, Testa AC, et al
   Response to the Correspondence by Xu et al. on "Diagnostic performance of ultrasound-guided biopsy for detecting recurrent or persistent cervical cancer after chemoradiotherapy: a prospective, single-center study" by Mascilini et al.
   Int J Gynecol Cancer. 2025 Dec 18:102882. doi: 10.1016/j.ijgc.2025.102882.
   PubMed    
   
   
   
7. WANG K, Zhai Q, Xie Y, Tian Y, et al
   Sentinel node mapping with carbon nanoparticles versus lymphadenectomy in early cervical cancer.
   Int J Gynecol Cancer. 2025;36:102881.
   PubMed     Abstract available
   
   
   
8. WU Q, Qiu X, Peng R
   Correspondence on "Role of the novel optoelectronic imaging tracing system in cervical cancer screening: preliminary outcomes of a multi-center study" by Xiao Shang et al.
   Int J Gynecol Cancer. 2025 Dec 16:102873. doi: 10.1016/j.ijgc.2025.102873.
   PubMed    
   
   
   
9. MATSUO K, Matsuzaki S, Roman LD
   Response to "Correspondence on 'Identifying the possible candidate population for adjuvant radiotherapy de-escalation for intermediate-risk cervical cancer' by Matsuo et al" by Hu Y and Fang Q.
   Int J Gynecol Cancer. 2025 Dec 5:102840. doi: 10.1016/j.ijgc.2025.102840.
   PubMed    
   
   
   
10. XU Q, Han J
    Correspondence on "Diagnostic performance of ultrasound-guided biopsy for detecting recurrent or persistent cervical cancer after chemoradiotherapy: a prospective, single-center study" by Mascilini et al.
    Int J Gynecol Cancer. 2025 Dec 5:102846. doi: 10.1016/j.ijgc.2025.102846.
    PubMed    
    
    
    
11. SONG Y, Ran G, Zeng R, Chen C, et al
    Global burden and temporal trends of cervical cancer in women aged 60 years and older, 1990-2021: a Global Burden of Disease study.
    Int J Gynecol Cancer. 2025;36:102851.
    PubMed     Abstract available
    
    
    
12. CONZUELO RODRIGUEZ G, Cremer ML, Soler M, Alfaro K, et al
    Long-term impact of cervical ablation in visual assessment of the squamocolumnar junction: implications for subsequent screening and follow-up.
    Int J Gynecol Cancer. 2025;35:102717.
    PubMed     Abstract available
    
    
    November 2025
13. PAN TL, Friko I, Mwinbe-Ere Der V, Gultekin M, et al
    Building cervical cancer screening capacity in low-resource settings: lessons from Techiman, Ghana.
    Int J Gynecol Cancer. 2025 Nov 28:102808. doi: 10.1016/j.ijgc.2025.102808.
    PubMed    
    
    
    
14. HU Y, Fang Q
    Correspondence on "Identifying the possible candidate population for adjuvant radiotherapy de-escalation for intermediate-risk cervical cancer" by Matsuo et al.
    Int J Gynecol Cancer. 2025 Nov 26:102831. doi: 10.1016/j.ijgc.2025.102831.
    PubMed    
    
    
    
15. MAYADEV JS, Albuquerque KV, Price JG, Marcrom S, et al
    ARTIA-Cervix: a prospective trial of adaptive radiation therapy for cervical cancer.
    Int J Gynecol Cancer. 2025 Nov 21:102823. doi: 10.1016/j.ijgc.2025.102823.
    PubMed     Abstract available
    
    
    
16. ZHOU J, Cai J, Li X, Liu C, et al
    Pelvic radiotherapy combined with immunotherapy and chemotherapy for stage IVB cervical cancer: a retrospective study.
    Int J Gynecol Cancer. 2025;36:102800.
    PubMed     Abstract available
    
    
    
17. PERALTA J, Caicedo L, Rodriguez J, Viveros-Carreno D, et al
    Oncological impact of pelvic vessels embolization in patients with locally advanced cervical cancer treated with concomitant chemoradiotherapy.
    Int J Gynecol Cancer. 2025;36:102776.
    PubMed     Abstract available
    
    
    
18. BAI F, Wu G, Qu X, Shen J, et al
    Optimal adjuvant radiotherapy strategy for cervical cancer: a multi-center database cohort study.
    Int J Gynecol Cancer. 2025;36:102791.
    PubMed     Abstract available
    
    
    
19. SIGNORELLI M, Secchi M
    Correspondence on "Clinical outcomes of external radiotherapy boost versus no boost to radiologically positive lymph nodes in FIGO stage IIIC cervical cancer" by Karthik S Rishi et al.
    Int J Gynecol Cancer. 2025 Nov 4:102777. doi: 10.1016/j.ijgc.2025.102777.
    PubMed    
    
    
    
20. O'HARA CA, Khoo ZKH, Dimech C, Chong NZ, et al
    Screening of human papilloma virus-related anogenital cancers in immunocompromised women: a systematic review of clinical practice guidelines.
    Int J Gynecol Cancer. 2025;35:102131.
    PubMed     Abstract available
    
    
    
21. FARZANEH F, Dastyar F, Mohammadi M, Hosseini MS, et al
    Long-term oral contraceptive use as a risk factor for high-grade cervical lesions in women with high-risk human papillomavirus: a retrospective cohort analysis.
    Int J Gynecol Cancer. 2025;35:102650.
    PubMed     Abstract available
    
    
    October 2025
22. MAMEDE I, Riya IJ, Piya IJ, Nohmi RL, et al
    Adjuvant, neoadjuvant, and surgical treatment for locally advanced cervical cancer: a Bayesian network meta-analysis.
    Int J Gynecol Cancer. 2025;36:102750.
    PubMed     Abstract available
    
    
    
23. MASCILINI F, Mburu A, Ciancia M, Moro F, et al
    Diagnostic performance of ultrasound-guided biopsy for detecting recurrent or persistent cervical cancer after chemoradiotherapy: a prospective, single-center study.
    Int J Gynecol Cancer. 2025;35:102752.
    PubMed     Abstract available
    
    
    
24. SON Y, Hong S, Jang W, Kim S, et al
    Global, regional, and national burden of cervical cancer in 2022 and projections to 2050: a population-based analysis of GLOBOCAN.
    Int J Gynecol Cancer. 2025;36:102751.
    PubMed     Abstract available
    
    
    
25. MATSUO K, Matsuzaki S, Roman LD
    Definition of intermediate risk cervical cancer and histology-specific survival interaction.
    Int J Gynecol Cancer. 2025 Oct 17:102749. doi: 10.1016/j.ijgc.2025.102749.
    PubMed    
    
    
    
26. PENG Y, Chen M, Liang T, Wang Y, et al
    Distribution and maturity of tertiary lymphoid structures predict recurrence-free survival in cervical cancer.
    Int J Gynecol Cancer. 2025;36:102718.
    PubMed     Abstract available
    
    
    
27. WRIGHT JD, Bizzarri N, Agarwal J, Chen L, et al
    Association of sentinel lymph node biopsy and isolated tumor cells in cervical cancer.
    Int J Gynecol Cancer. 2025 Oct 11:102721. doi: 10.1016/j.ijgc.2025.102721.
    PubMed     Abstract available
    
    
    
28. SHANG X, Qiu L, Liu Y, Chen H, et al
    Role of the novel optoelectronic imaging tracing system in cervical cancer screening: preliminary outcomes of a multi-center study.
    Int J Gynecol Cancer. 2025;35:102716.
    PubMed     Abstract available
    
    
    
29. BAIOCCHI G, Zanvettor PH, Lopes A, Ribeiro R, et al
    Reconsidering adjuvant radiotherapy in intermediate-risk cervical cancer: findings from the CIRCOL study group.
    Int J Gynecol Cancer. 2025;35:102723.
    PubMed     Abstract available
    
    
    
30. MANNING-GEIST BL, Miller M, Dagher C, Kim SH, et al
    Evaluation of toxicity after radical hysterectomy or trachelectomy and post-operative pelvic intensity-modulated radiation therapy with concurrent chemotherapy for cervical cancer.
    Int J Gynecol Cancer. 2025;35:102712.
    PubMed     Abstract available
    
    
    
31. WANG L, Wei Y, Wu Q
    Correspondence on "Prognostic impact of para-aortic surgical staging in stage IIIC1 cervical cancer according to the FIGO 2018 classification" by El-Baz et al.
    Int J Gynecol Cancer. 2025 Oct 4:102706. doi: 10.1016/j.ijgc.2025.102706.
    PubMed    
    
    
    
32. DIAZ ES, Levin G, Aristizabal B, Fernandes A, et al
    Silicon dioxide, sodium selenite and citric acid vaginal gel, HPV infection, and cervical preinvasive disease: a narrative review.
    Int J Gynecol Cancer. 2025;35:102021.
    PubMed     Abstract available
    
    
    September 2025
33. CERDA V, Rimel BJ, Mercer J, Thompson MA, et al
    Exploratory evaluation of the somatic and immunologic landscape of primary and metastatic cervical cancer to better inform future clinical trial development.
    Int J Gynecol Cancer. 2025;35:102677.
    PubMed     Abstract available
    
    
    
34. MATSUO K, Matsuzaki S, Nagase Y, Keymeulen S, et al
    Identifying the possible candidate population for adjuvant radiotherapy de-escalation for intermediate-risk cervical cancer.
    Int J Gynecol Cancer. 2025;35:102674.
    PubMed     Abstract available
    
    
    
35. EL-BAZ E, Ouldamer L, Touboul C, Lavoue V, et al
    Prognostic impact of para-aortic surgical staging in stage IIIC1 cervical cancer according to the FIGO 2018 classification.
    Int J Gynecol Cancer. 2025;35:102675.
    PubMed     Abstract available
    
    
    
36. KOBAYASHI M, Nakagawa S, Masuda T, Kakuda M, et al
    Clinical and pathological characteristics and outcomes of small cell neuroendocrine carcinoma of the uterine cervix.
    Int J Gynecol Cancer. 2025;35:102011.
    PubMed     Abstract available
    
    
    
37. BAEK JY, Park W, Cho WK, Kim HS, et al
    Surgery plus post-operative radiotherapy versus definitive chemoradiotherapy in locally advanced endocervical adenocarcinoma.
    Int J Gynecol Cancer. 2025;35:102013.
    PubMed     Abstract available
    
    
    
38. GAO X, Kong Y, Ning Y, Cui Z, et al
    Clinical characteristics and prognosis of rhabdomyosarcoma in the female reproductive system: a population-based analysis using SEER data.
    Int J Gynecol Cancer. 2025;35:101989.
    PubMed     Abstract available
    
    
    August 2025
39. MURAD V, Chawla T, Brien CO
    The missing link in SHAPE: standardizing magnetic resonance imaging assessment of stromal invasion for cervical cancer.
    Int J Gynecol Cancer. 2025;35:102133.
    PubMed    
    
    
    
40. ISMAIL M, Refky B, Mostafa N, Elazab M, et al
    From silence to action: Egypt's path to national cervical cancer prevention.
    Int J Gynecol Cancer. 2025 Aug 26:102121. doi: 10.1016/j.ijgc.2025.102121.
    PubMed    
    
    
    July 2025
41. RISHI KS, Harshita K, Spandana P, Donapati PKR, et al
    Clinical outcomes of external radiotherapy boost versus no boost to radiologically positive lymph nodes in FIGO stage IIIC cervical cancer.
    Int J Gynecol Cancer. 2025;35:102030.
    PubMed     Abstract available
    
    
    
42. SUZUKI DA, Gouveia MC, Bonalumi Dos Santos M, Scaranti M, et al
    Beyond survival: reclaiming quality of life after cervical cancer treatment.
    Int J Gynecol Cancer. 2025;35:102026.
    PubMed    
    
    
    
43. MARTINS JC, Gouveia MC, Bonadio RC, Scaranti M, et al
    When the blood speaks first: circulating tumor DNA as a biomarker in locally advanced cervical cancer.
    Int J Gynecol Cancer. 2025;35:102020.
    PubMed    
    
    
    
44. VIVEROS-CARRENO D, Agusti N, Rodriguez J, Mora-Soto N, et al
    Inadvertent cervical cancer: a narrative review.
    Int J Gynecol Cancer. 2025;35:101986.
    PubMed     Abstract available
    
    
    
45. HAGEN KK, Lie AK, Dahl GF, Eyjolfsdottir B, et al
    The Silva pattern-based classification and oncological outcomes in women undergoing fertility-sparing surgery for early-stage cervical cancer.
    Int J Gynecol Cancer. 2025;35:102012.
    PubMed     Abstract available
    
    
    
46. CRIFASE C, Parker J, Zhang L, Shang S, et al
    Is cone length a risk factor for internal margin positivity in high-grade squamous intraepithelial lesions based on age?
    Int J Gynecol Cancer. 2025;35:101825.
    PubMed     Abstract available
    
    
    
47. HSIAO KY, Lin HL, Chen HM, Chen CC, et al
    Accuracy of human papillomavirus testing using self-collected urine samples for detecting high-grade squamous intra-epithelial lesion or worse: a diagnostic meta-analysis.
    Int J Gynecol Cancer. 2025;35:101904.
    PubMed     Abstract available
    
    
    June 2025
48. CHIKAZAWA K, Ko H, Imai K, Kuwata T, et al
    What should be the next control arm in prospective studies for locally advanced cervical cancer?
    Int J Gynecol Cancer. 2025;35:101981.
    PubMed    
    
    
    
49. BOGANI G, Scambia G, Malzoni M, Casarin J, et al
    Erratum to 'Chemo-conization in Early-sTage cERvical caNcer >2 cm scheduled for fertility-sparing approach: an analysis of the ETERNITY project' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101643].
    Int J Gynecol Cancer. 2025 Jun 5:101960. doi: 10.1016/j.ijgc.2025.101960.
    PubMed    
    
    
    May 2025
50. KIM YJ, Yoo YJ, Jang JY, Kim YM, et al
    Follow-up strategies for patients with cervical cancer who achieved complete response after definitive chemoradiotherapy.
    Int J Gynecol Cancer. 2025 May 21:101933. doi: 10.1016/j.ijgc.2025.101933.
    PubMed     Abstract available
    
    
    
51. LI J, Cai M, Xie C, Ding S, et al
    Survival outcomes and safety of nimotuzumab combined with radiotherapy +/- chemotherapy for locally advanced cervical cancer.
    Int J Gynecol Cancer. 2025;35:101930.
    PubMed     Abstract available
    
    
    
52. MEI X, Fobian SF, IJff M, Crezee J, et al
    High human papillomavirus viral load and local immune dysregulation are associated with poor clinical outcomes in patients with cervical cancer.
    Int J Gynecol Cancer. 2025;35:101924.
    PubMed     Abstract available
    
    
    
53. GUERRA RA, Tucker LY, Littell R, Kay AH, et al
    Long-term impact of surgical route and tumor size on risk of recurrence among early-stage cervical cancer patients in a managed care population.
    Int J Gynecol Cancer. 2025 May 10:101928. doi: 10.1016/j.ijgc.2025.101928.
    PubMed     Abstract available
    
    
    
54. DOSTALEK L, Brynda D, Marek R, Hederlingova J, et al
    Regression of high-grade squamous intraepithelial cervical lesions and associated risk factors (RECER).
    Int J Gynecol Cancer. 2025;35:101768.
    PubMed     Abstract available
    
    
    April 2025
55. FRENEL JS, Roynard T, Loaec C, Ray-Coquard I, et al
    Pocket guide based on the TNM and FIGO staging systems for classifying patients with locally advanced cervical cancer: a practical tool from the GINECO group for quick and easy management.
    Int J Gynecol Cancer. 2025;35:101908.
    PubMed    
    
    
    
56. FALLAH PN, Salcedo MP, Nhacule E, Utui Y, et al
    A randomized clinical trial to assess the effectiveness of thermal ablation versus loop electrosurgical excision procedure for cervical cancer risk reduction in women living with HIV in Mozambique.
    Int J Gynecol Cancer. 2025 Apr 26:101905. doi: 10.1016/j.ijgc.2025.101905.
    PubMed     Abstract available
    
    
    
57. ZEEVI G, Eitan R
    The art of prevention: merging creativity and medicine to transform cervical cancer awareness.
    Int J Gynecol Cancer. 2025;35:101909.
    PubMed    
    
    
    
58. KACPERCZYK-BARTNIK J, El Hajj H, Toth I, Bizzarri N, et al
    Declaration on cervical cancer elimination: literature review and perspectives from early-career clinicians.
    Int J Gynecol Cancer. 2025;35:101902.
    PubMed     Abstract available
    
    
    
59. NAVARRO AS, Ricotta G, Gauroy E, Martinez A, et al
    Urinary reconstruction using enterocystoplasty after partial cystectomy in surgical recurrence of cervical cancer.
    Int J Gynecol Cancer. 2025;35:101813.
    PubMed    
    
    
    
60. HEMIDA R, Barakat R, Nabil H, Hasan M, et al
    Cervical cancer elimination in low-resource countries: low-cost strategy.
    Int J Gynecol Cancer. 2025 Apr 11:101828. doi: 10.1016/j.ijgc.2025.101828.
    PubMed    
    
    
    
61. LEE J, Lin JB, Wang CH, Lin WH, et al
    Whole-uterine versus individualized-uterine radiotherapy in locally advanced cervical cancer: clinical outcome and toxicity.
    Int J Gynecol Cancer. 2025;35:101817.
    PubMed     Abstract available
    
    
    
62. FALLAH PN, Citonje-Msadabwe S, Fundafunda S, Schmeler KM, et al
    Scale-up of cervical cancer prevention services in Zambia.
    Int J Gynecol Cancer. 2025;35:101816.
    PubMed    
    
    
    
63. BIZZARRI N, Querleu D, Ramirez PT, Plante M, et al
    Minimally invasive simple hysterectomy in low-risk cervical cancer: a single-arm trial with stopping rules (ENGOT-cx23/MITO/LASH trial).
    Int J Gynecol Cancer. 2025;35:101818.
    PubMed     Abstract available
    
    
    
64. LOU J, Li Y, Li R, Guo Y, et al
    Association between magnetic resonance imaging-measured bone marrow cellularity and clinical outcomes among patients with cervical cancer treated with programmed cell death protein-1 inhibitors.
    Int J Gynecol Cancer. 2025;35:101808.
    PubMed     Abstract available
    
    
    
65. TESFAI FM, Yongue G, Chandrasekaran D, Francis N, et al
    Methods of surgical quality assurance in cervical and endometrial cancer trials: a systematic review and meta-analysis.
    Int J Gynecol Cancer. 2025;35:100018.
    PubMed     Abstract available
    
    
    March 2025
66. HUANG Y, Yoh K, Szamreta EA, Xu X, et al
    Patterns of pembrolizumab use for recurrent cervical cancer.
    Int J Gynecol Cancer. 2025;35:101802.
    PubMed     Abstract available
    
    
    
67. PAVONE M, Baby B, Carles E, Innocenzi C, et al
    Critical view of safety assessment in sentinel node dissection for endometrial and cervical cancer: artificial intelligence to enhance surgical safety and lymph node detection (LYSE study).
    Int J Gynecol Cancer. 2025;35:101789.
    PubMed     Abstract available
    
    
    
68. MORICE P, Gouy S, Plante M, Abu-Rustum N, et al
    Neoadjuvant chemotherapy in stage IB2 to IB3 cervical cancer: because we can or because we must?
    Int J Gynecol Cancer. 2025 Mar 14:101770. doi: 10.1016/j.ijgc.2025.101770.
    PubMed    
    
    
    
69. LIAO J, Xu T, Zhou J, Xiao N, et al
    The impact of chemotherapy on survival in patients aged >/=65 years with locoregionally cervical cancer who undergo radiotherapy: a Surveillance, Epidemiology, and End Results database analysis.
    Int J Gynecol Cancer. 2025 Mar 3:101747. doi: 10.1016/j.ijgc.2025.101747.
    PubMed     Abstract available
    
    
    
70. SALVO G, Meyer LA, Gonzales NR, Frumovitz M, et al
    Neuroendocrine cervical carcinomas: genomic insights, controversies in treatment strategies, and future directions: a NeCTuR study.
    Int J Gynecol Cancer. 2025;35:101639.
    PubMed     Abstract available
    
    
    
71. DE VITIS LA, Schivardi G, Gaeta A, Caruso G, et al
    External validation of the annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.
    Int J Gynecol Cancer. 2025 Mar 1:101756. doi: 10.1016/j.ijgc.2025.101756.
    PubMed     Abstract available
    
    
    
72. COLLIER E, Soberanis Pina P, McMullen M, Gonzalez-Ochoa E, et al
    Circulating human papillomavirus DNA sequencing as a biomarker of response in advanced cervical cancer.
    Int J Gynecol Cancer. 2025 Mar 1:101755. doi: 10.1016/j.ijgc.2025.101755.
    PubMed     Abstract available
    
    
    February 2025
73. LEITAO MM JR, Bixel KL, Chase DM, Quick A, et al
    ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer.
    Int J Gynecol Cancer. 2025 Feb 28:101760. doi: 10.1016/j.ijgc.2025.101760.
    PubMed     Abstract available
    
    
    
74. BIZZARRI N, Guidi G, Pavone M, Pedone Anchora L, et al
    Laparoscopic para-uterine lymphovascular tissue sentinel lymph node biopsy with indocyanine green in cervical cancer.
    Int J Gynecol Cancer. 2025 Feb 27:101744. doi: 10.1016/j.ijgc.2025.101744.
    PubMed    
    
    
    
75. MANZOUR N, Chiva L, Zanagnolo V, Capilna ME, et al
    SUCCOR 10 years: a decade's perspective on radical hysterectomy outcomes in cervical cancer.
    Int J Gynecol Cancer. 2025 Feb 6:101690. doi: 10.1016/j.ijgc.2025.101690.
    PubMed     Abstract available
    
    
    
76. YARZA R, Kountouri M, Guedes H, O'Gorman C, et al
    Progression-free survival as a potential surrogate end point for overall survival in advanced cervical carcinoma.
    Int J Gynecol Cancer. 2025;35:100012.
    PubMed     Abstract available
    
    
    
77. MILLER KM, Liu C, Zhou Q, Iasonos A, et al
    RELEVANT-C study: patient-reported prevalence of lower extremity lymphedema after sentinel lymph node mapping vs lymphadenectomy after surgery for early-stage cervical cancer.
    Int J Gynecol Cancer. 2025;35:100063.
    PubMed     Abstract available
    
    
    
78. TSIBULAK I, Collins A, Hsu HC, Chacon E, et al
    Global survey on training and practice in sentinel lymph node mapping for endometrial and cervical cancer among early-career gynecologic oncologists.
    Int J Gynecol Cancer. 2025;35:100050.
    PubMed     Abstract available
    
    
    
79. DITTO A, Dri M, Leone Roberti Maggiore U, Raspagliesi F, et al
    Reply to "Correspondence on 'Fertility-sparing treatment with conization versus radical hysterectomy in patients with early-stage cervical cancer: Inverse propensity score-weighted analysis,' by Ditto et al" by Phillippe Morice and Sebastien Gouy.
    Int J Gynecol Cancer. 2025;35:100026.
    PubMed    
    
    
    
80. MATSUO K, Agarwal J, Chen L, Pino C, et al
    Modified radical hysterectomy for stage IB1 (
    Int J Gynecol Cancer. 2025 Feb 1:101676. doi: 10.1016/j.ijgc.2025.101676.
    PubMed     Abstract available
    
    
    January 2025
81. LIEN CJ, Lien WC
    Wunderlich syndrome as a presenting symptom in cervical cancer.
    Int J Gynecol Cancer. 2025 Jan 30:101675. doi: 10.1016/j.ijgc.2025.101675.
    PubMed    
    
    
    
82. LIMA WAL, Gouveia MC, Oliveira LCM, Scaranti M, et al
    Revolutionizing first-line cervical cancer treatment: bevacizumab, immunotherapy, and emerging insights.
    Int J Gynecol Cancer. 2025 Jan 28:101661. doi: 10.1016/j.ijgc.2025.101661.
    PubMed    
    
    
    
83. GUIDI G, Vargiu V, Ammar S, Bizzarri N, et al
    Radical hysterectomy and ovarian transposition during cesarean section for newly diagnosed cervical cancer in pregnancy.
    Int J Gynecol Cancer. 2025 Jan 25:101663. doi: 10.1016/j.ijgc.2025.101663.
    PubMed    
    
    
    
84. BOGANI G, Scambia G, Malzoni M, Casarin J, et al
    Chemo-conization in Early-sTage cERvical caNcer >2 cm scheduled for fertilItY-sparing approach: an analysis of the ETERNITY project.
    Int J Gynecol Cancer. 2025 Jan 17:101643. doi: 10.1016/j.ijgc.2025.101643.
    PubMed     Abstract available
    
    
    
85. LEETANAPORN K, Hanprasertpong J
    Addition of chemotherapy to radiation is associated with improved survival in older patients with cervical cancer: a Surveillance, Epidemiology, and End Results database analysis.
    Int J Gynecol Cancer. 2025 Jan 9:101633. doi: 10.1016/j.ijgc.2025.101633.
    PubMed     Abstract available
    
    
    
86. VILLEGAS SANCHEZ S, Ramirez Cantillo S, Hernandez Aramburo PM, Hernandez JM, et al
    Cervical cancer prevention in Colombian indigenous communities, a project by Acacia de Vida Foundation.
    Int J Gynecol Cancer. 2025 Jan 9:101623. doi: 10.1016/j.ijgc.2024.101623.
    PubMed    
    
    
    
87. SAHLI L, Siegenthaler F, Buchi CA, Hofer S, et al
    Role of pre-sacral sentinel lymph nodes in endometrium and cervical cancer: experience with minimally invasive indocyanine green sentinel lymph node mapping.
    Int J Gynecol Cancer. 2025;35:100032.
    PubMed     Abstract available
    
    
    
88. MORICE P, Gouy S
    Correspondence on "Fertility-sparing treatment with conization versus radical hysterectomy in patients with early-stage cervical cancer: inverse propensity score weighted analysis," by Ditto et al.
    Int J Gynecol Cancer. 2025;35:100028.
    PubMed    
    
    
    
89. AFROZE L, Rahman MS
    Men's role in women's health: Engaging male partners in cervical cancer prevention efforts in low-to-middle-income countries.
    Int J Gynecol Cancer. 2025;35:100021.
    PubMed    
    
    
    
90. PRETI M, Lewis F, Carcopino X, Bevilacqua F, et al
    Vulvar inspection at the time of cervical cancer screening: European Society of Gynaecological Oncology (ESGO), International Society for the Study of Vulvovaginal Disease (ISSVD), European College for the Study of Vulval Disease (ECSVD), and European
    Int J Gynecol Cancer. 2025;35:100007.
    PubMed     Abstract available
    
    
    
91. RAMIREZ PT
    Minimally invasive surgery for simple hysterectomy in early-stage cervical cancer: 'SHAPing' a path forward.
    Int J Gynecol Cancer. 2025;35:101619.
    PubMed    
    
    
    
92. ANAKWENZE C, Kalra A, Lumley C, Chinniah G, et al
    Cervical cancer stage distribution and survival outcomes in Africa: a systematic review and meta-analysis.
    Int J Gynecol Cancer. 2025;35:100008.
    PubMed     Abstract available
    
    
    
93. PLANTE M, Mahner S, Sebastianelli A, Bessette P, et al
    Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial.
    Int J Gynecol Cancer. 2025;35:100001.
    PubMed     Abstract available
    
    
    December 2024
94. ALVARENGA-BEZERRA V, Santia MC, Meschini T, Deavers M, et al
    Challenges in differentiating between primary cervical cancer versus stage II endometrial cancer.
    Int J Gynecol Cancer. 2024;34:1976-1979.
    PubMed    
    
    
    
95. NASIOUDIS D, Latif NA, Gysler S, Giuntoli RL 2nd, et al
    Premature adoption of adjuvant chemotherapy for locally advanced cervical carcinoma before the OUTBACK trial: cautionary tale on outcomes.
    Int J Gynecol Cancer. 2024;34:1874-1880.
    PubMed     Abstract available
    
    
    
96. LINDEGAARD JC, Petric P, Tan LT, Hoskin P, et al
    Are we making progress in curing advanced cervical cancer-again?
    Int J Gynecol Cancer. 2024;34:1940-1945.
    PubMed     Abstract available
    
    
    
97. GOLIA D'AUGE T, Caruso G, Laudani ME, Nazzaro L, et al
    Para-aortic lymph node recurrence in surgically treated early-stage cervical cancer without para-aortic lymph node surgical staging.
    Int J Gynecol Cancer. 2024;34:1867-1873.
    PubMed     Abstract available
    
    
    
98. PAN TL, Pareja R, Chiva L, Rodriguez J, et al
    Accuracy of pre-operative tumor size assessment compared to final pathology and frequency of adjuvant treatment in patients with FIGO 2018 stage IB2 cervical cancer.
    Int J Gynecol Cancer. 2024;34:1861-1866.
    PubMed     Abstract available
    
    
    November 2024
99. MORETTI-MARQUES R, Alvarenga-Bezerra V, de Cillo PE, Akaishi DY, et al
    First robotic radical trachelectomy for cervical cancer using the Hugo RAS platform.
    Int J Gynecol Cancer. 2024 Nov 13:ijgc-2024-005895.
    PubMed    
    
    
    
100. MEKURIA SF, Biazin H, Abebe T, Borgfeldt C, et al
     Comparing visual inspection with acetic acid, with and without Lugol's Iodine for triage of HPV self-sample positive women in Ethiopia: a randomized controlled trial.
     Int J Gynecol Cancer. 2024;34:1691-1697.
     PubMed     Abstract available
     
     
     
101. CHEN M, Han L, Wang Y, Chen Y, et al
     Association between Silva pattern-based classification and endocervical adenocarcinoma: a systematic review and meta-analysis.
     Int J Gynecol Cancer. 2024;34:1704-1710.
     PubMed     Abstract available
     
     
     
102. BIZZARRI N, Abu-Rustum NR, Plante M, Ramirez PT, et al
     Assessing minimally invasive simple hysterectomy in low risk cervical cancer: set up for the LASH trial.
     Int J Gynecol Cancer. 2024;34:1805-1808.
     PubMed     Abstract available
     
     
     
103. CHEN M, Han L, Wang Y, Chen Y, et al
     Association between Silva pattern-based classification and endocervical adenocarcinoma: a systematic review and meta-analysis.
     Int J Gynecol Cancer. 2024;34:1704-1710.
     PubMed     Abstract available
     
     
     
104. CHAMBULE S, Rangeiro R, Batman S, Lathrop E, et al
     Scaling cervical cancer screening in Mozambique: analysis of loop electrosurgical excision procedure (LEEP) specimens.
     Int J Gynecol Cancer. 2024;34:1698-1703.
     PubMed     Abstract available
     
     
     
105. MEKURIA SF, Biazin H, Abebe T, Borgfeldt C, et al
     Comparing visual inspection with acetic acid, with and without Lugol's Iodine for triage of HPV self-sample positive women in Ethiopia: a randomized controlled trial.
     Int J Gynecol Cancer. 2024;34:1691-1697.
     PubMed     Abstract available
     
     
     October 2024
106. PAN TL, Pareja R, Chiva L, Rodriguez J, et al
     Accuracy of pre-operative tumor size assessment compared to final pathology and frequency of adjuvant treatment in patients with FIGO 2018 stage IB2 cervical cancer.
     Int J Gynecol Cancer. 2024 Oct 23:ijgc-2024-005986.
     PubMed     Abstract available
     
     
     
107. AFROZE L, Rahman MS
     Community-based interventions to reduce cervical cancer in low- and middle-income countries: a call to action.
     Int J Gynecol Cancer. 2024 Oct 21:ijgc-2024-006188.
     PubMed    
     
     
     
108. GOLIA D'AUGE T, Caruso G, Laudani ME, Nazzaro L, et al
     Para-aortic lymph node recurrence in surgically treated early-stage cervical cancer without para-aortic lymph node surgical staging.
     Int J Gynecol Cancer. 2024 Oct 8:ijgc-2024-005950. doi: 10.1136/ijgc-2024-005950
     PubMed     Abstract available
     
     
     
109. GOUVEIA MC, Graziano LM, Leis LV, Scaranti M, et al
     The evolving landscape of locally advanced cervical cancer treatment.
     Int J Gynecol Cancer. 2024 Oct 7:ijgc-2024-006128. doi: 10.1136/ijgc-2024-006128
     PubMed    
     
     
     
110. SILVA FILHO ALD, Reis Romualdo G, Pinhati MES, Neves GL, et al
     Exploring cervical cancer mortality in Brazil: an ecological study on socioeconomic and healthcare factors.
     Int J Gynecol Cancer. 2024 Oct 4:ijgc-2024-005738. doi: 10.1136/ijgc-2024-005738
     PubMed     Abstract available
     
     
     
111. GAO H, Wu H, Zhang Y, Li X, et al
     Long-term survival in patients with para-aortic metastatic cervical cancer receiving simultaneous integrated boost chemoradiation to positive lymph nodes: a single-center experience.
     Int J Gynecol Cancer. 2024;34:1536-1546.
     PubMed     Abstract available
     
     
     September 2024
112. CHAMBULE S, Rangeiro R, Batman S, Lathrop E, et al
     Scaling cervical cancer screening in Mozambique: analysis of loop electrosurgical excision procedure (LEEP) specimens.
     Int J Gynecol Cancer. 2024 Sep 25:ijgc-2024-005827.
     PubMed     Abstract available
     
     
     
113. DITTO A, Martinelli F, Dri M, Maggiore ULR, et al
     Fertility-sparing treatment with conization versus radical hysterectomy in patients with early-stage cervical cancer: inverse propensity score weighted analysis.
     Int J Gynecol Cancer. 2024 Sep 23:ijgc-2024-005418.
     PubMed     Abstract available
     
     
     
114. EL HAJJ H, Hemida R, Taumberger N, Friko I, et al
     Advancing cervical cancer prevention in Africa: ESGO's strategic initiatives and collaborative efforts.
     Int J Gynecol Cancer. 2024 Sep 18:ijgc-2024-006059.
     PubMed    
     
     
     
115. MANNING-GEIST BL, Mueller JJ
     Raising the bar on collaborative science: the SENECA study and sentinel lymph node mapping.
     Int J Gynecol Cancer. 2024;34:1322-1323.
     PubMed    
     
     
     
116. ZHANG L, Zhang X, Sui L, Cong Q, et al
     Risk factors for vaginal squamous intra-epithelial lesions in women with high-grade cervical lesions.
     Int J Gynecol Cancer. 2024;34:1344-1348.
     PubMed     Abstract available
     
     
     
117. GUO XM, Roman LD, Matsuo K
     Considerations for route of hysterectomy in low-risk cervical cancer.
     Int J Gynecol Cancer. 2024;34:1481.
     PubMed    
     
     
     
118. MATSUO K, Shimada M, Matsuzaki S, Machida H, et al
     Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer.
     Int J Gynecol Cancer. 2024;34:1349-1358.
     PubMed     Abstract available
     
     
     August 2024
119. BIZZARRI N, Abu-Rustum NR, Plante M, Ramirez PT, et al
     Assessing minimally invasive simple hysterectomy in low risk cervical cancer: set up for the LASH trial.
     Int J Gynecol Cancer. 2024 Aug 28:ijgc-2024-005941.
     PubMed     Abstract available
     
     
     
120. GAO H, Wu H, Zhang Y, Li X, et al
     Long-term survival in patients with para-aortic metastatic cervical cancer receiving simultaneous integrated boost chemoradiation to positive lymph nodes: a single-center experience.
     Int J Gynecol Cancer. 2024 Aug 28:ijgc-2024-005664.
     PubMed     Abstract available
     
     
     
121. CARUSO G, Wagar MK, Hsu HC, Hoegl J, et al
     Cervical cancer: a new era.
     Int J Gynecol Cancer. 2024 Aug 7:ijgc-2024-005579. doi: 10.1136/ijgc-2024-005579
     PubMed     Abstract available
     
     
     
122. ZAMBRANO HARVEY AR, Galvis-Catano LM, Bonilla-Escobar FJ, Zapata Izquierdo MA, et al
     Intercultural dialogues and multilevel strategies for cervical cancer prevention for the Arhuacos indigenous community in Colombia.
     Int J Gynecol Cancer. 2024 Aug 7:ijgc-2024-005871. doi: 10.1136/ijgc-2024-005871
     PubMed    
     
     
     
123. MATSUO K, Shimada M, Matsuzaki S, Machida H, et al
     Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer.
     Int J Gynecol Cancer. 2024 Aug 6:ijgc-2024-005597. doi: 10.1136/ijgc-2024-005597
     PubMed     Abstract available
     
     
     
124. PEREZ VILLENA JF, Sanchez Salcedo M, Montoya Guivin A, Villoslada Terrones V, et al
     First workshop on cervix cancer surgery in Latin America: a hands-on experience from Lima, Peru.
     Int J Gynecol Cancer. 2024;34:1294-1295.
     PubMed    
     
     
     
125. SALANI R, McCormack M, Kim YM, Ghamande S, et al
     A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
     Int J Gynecol Cancer. 2024;34:1140-1148.
     PubMed     Abstract available
     
     
     July 2024
126. LEE ST, Lee YL, Chung CH, Chien WC, et al
     Cervical cancer and risk of dementia: real-world insights from a nationwide cohort study in Taiwan.
     Int J Gynecol Cancer. 2024 Jul 23:ijgc-2024-005408.
     PubMed     Abstract available
     
     
     
127. LINDEGAARD JC, Petric P, Tan LT, Hoskin P, et al
     Are we making progress in curing advanced cervical cancer-again?
     Int J Gynecol Cancer. 2024 Jul 10:ijgc-2024-005572.
     PubMed     Abstract available
     
     
     
128. VAN DEN BERG MC, Berg HF, Stokowy T, Hoivik EA, et al
     Expression patterns of mismatch repair proteins in cervical cancer uncover independent prognostic value of MSH-2.
     Int J Gynecol Cancer. 2024;34:993-1000.
     PubMed     Abstract available
     
     
     
129. FRUHAUF F, Cibula D, Kocian R, Zikan M, et al
     Diagnostic performance of ultrasonography in pre-operative assessment of lymph nodes in patients with cervical cancer.
     Int J Gynecol Cancer. 2024;34:985-992.
     PubMed     Abstract available
     
     
     June 2024
130. AKYILDIZ A, Gultekin M, Yigit E, Demir E, et al
     Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group.
     Int J Gynecol Cancer. 2024 Jun 30:ijgc-2024-005419.
     PubMed     Abstract available
     
     
     
131. AGUSTI N, Viveros-Carreno D, Melamed A, Pareja R, et al
     Adjuvant external beam radiotherapy combined with brachytherapy for intermediate-risk cervical cancer.
     Int J Gynecol Cancer. 2024 Jun 25:ijgc-2024-005570.
     PubMed     Abstract available
     
     
     
132. GUO XM, Roman LD, Matsuo K
     Considerations for route of hysterectomy in low-risk cervical cancer.
     Int J Gynecol Cancer. 2024 Jun 23:ijgc-2024-005745.
     PubMed    
     
     
     
133. SALANI R, McCormack M, Kim YM, Ghamande S, et al
     A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04).
     Int J Gynecol Cancer. 2024 Jun 10:ijgc-2024-005588.
     PubMed     Abstract available
     
     
     
134. DIGGS A, Huang Y, Melamed A, Szamreta E, et al
     Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer.
     Int J Gynecol Cancer. 2024 Jun 8:ijgc-2023-004860. doi: 10.1136/ijgc-2023-004860
     PubMed     Abstract available
     
     
     
135. PAREJA R
     Vaginal radical trachelectomy: is now the end of an era?
     Int J Gynecol Cancer. 2024;34:806-807.
     PubMed    
     
     
     May 2024
136. NISTOR SI, El Tawab S, Zouridis A, Ferrari F, et al
     Minimally invasive surgery in the management of early stage cervical cancer after the publication of SHAPE trial.
     Int J Gynecol Cancer. 2024 May 31:ijgc-2024-005724.
     PubMed    
     
     
     April 2024
137. SHI V, Grover S, Huang Y, Thaker PH, et al
     Accuracy of surveillance serum squamous cell carcinoma antigen for cervical cancer recurrence after definitive chemoradiation.
     Int J Gynecol Cancer. 2024 Apr 29:ijgc-2024-005303.
     PubMed     Abstract available
     
     
     
138. CHARNALIA M, Chopra S, Mulani J, Popat P, et al
     RECIST 1.1 versus clinico-radiological response assessment for locally advanced cervical cancer: implications on interpreting survival outcomes of future trials.
     Int J Gynecol Cancer. 2024 Apr 22:ijgc-2024-005336.
     PubMed     Abstract available
     
     
     
139. ROSATI A, Certelli C, Ferrandina G, Fanfani F, et al
     Minimally invasive adrenalectomy: a personalized surgical approach in recurrent cervical cancer.
     Int J Gynecol Cancer. 2024 Apr 22:ijgc-2023-005241.
     PubMed    
     
     
     
140. KOHLER C, Plaikner A, Siegler K, Hertel H, et al
     Radical vaginal trachelectomy: long-term oncologic and fertility outcomes in patients with early cervical cancer.
     Int J Gynecol Cancer. 2024 Apr 10:ijgc-2024-005274.
     PubMed     Abstract available
     
     
     
141. HANEY K, Ismail-Pratt I, Ng JS, Schmeler KM, et al
     The International Gynecologic Cancer Society Preinvasive Certificate Program: building a skilled workforce for the detection and treatment of cervical pre-cancer.
     Int J Gynecol Cancer. 2024;34:637-638.
     PubMed    
     
     
     
142. KEMAH BL, Bhagat N, Pandya A, Sullivan R, et al
     Training the gynecologic oncologists of the future - challenges and opportunities.
     Int J Gynecol Cancer. 2024;34:619-626.
     PubMed     Abstract available
     
     
     March 2024
143. WESS B, Kohler C, Plaikner A, El-Safadi S, et al
     Comparative study using indocyanine green and patent blue dye for sentinel lymph node biopsy in patients with early-stage cervical cancer.
     Int J Gynecol Cancer. 2024 Mar 14:ijgc-2023-005206.
     PubMed     Abstract available
     
     
     
144. DEL M, Illac C, Morisseau M, Angeles MA, et al
     Intraepithelial tumor-infiltrating lymphocytes shape loco-regional PET/CT spread of locally advanced cervical cancer.
     Int J Gynecol Cancer. 2024 Mar 12:ijgc-2023-004677.
     PubMed     Abstract available
     
     
     
145. JAYRAJ AS, Singhal S
     The beginning of the end for cervical cancer in India.
     Int J Gynecol Cancer. 2024 Mar 7:ijgc-2024-005420. doi: 10.1136/ijgc-2024-005420
     PubMed    
     
     
     
146. VIVEROS-CARRENO D, Pareja R, Plante M
     De-escalation of surgical radicality for non-fertility preserving management in patients with early-stage cervical cancer: a systematic review.
     Int J Gynecol Cancer. 2024;34:386-392.
     PubMed     Abstract available
     
     
     
147. PETERS I, Marchetti C, Scambia G, Fagotti A, et al
     New windows of surgical opportunity for gynecological cancers in the era of targeted therapies.
     Int J Gynecol Cancer. 2024;34:352-362.
     PubMed     Abstract available
     
     
     February 2024
148. FOTOPOULOU C, Eriksson AG, Planchamp F, Morice P, et al
     European Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management.
     Int J Gynecol Cancer. 2024 Feb 23:ijgc-2024-005293.
     PubMed    
     
     
     
149. BIZZARRI N, Obermair A, Hsu HC, Chacon E, et al
     Consensus on surgical technique for sentinel lymph node dissection in cervical cancer.
     Int J Gynecol Cancer. 2024 Feb 20:ijgc-2023-005151.
     PubMed     Abstract available
     
     
     
150. VAZQUEZ-VICENTE D, Boria F, Castellanos T, Gutierrez M, et al
     SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer.
     Int J Gynecol Cancer. 2024;34:203-208.
     PubMed     Abstract available
     
     
     
151. DELLINO M, Cerbone M, Fortunato F, Capursi T, et al
     Incidence of pre-neoplastic and neoplastic lesions of the cervix before and after the COVID-19 pandemic.
     Int J Gynecol Cancer. 2024;34:224-228.
     PubMed     Abstract available
     
     
     
152. KHURANA N, Frumovitz M, Flores Legarreta A, Ramalingam P, et al
     Impact of pelvic radiation therapy in patients with early neuroendocrine cervical carcinoma and no residual disease in the radical hysterectomy specimen: a NeCTuR study.
     Int J Gynecol Cancer. 2024;34:209-215.
     PubMed     Abstract available
     
     
     
153. DOSTALEK L, Freitag P, Slovackova M, Zima T, et al
     HPV testing as an effective triage strategy in the follow-up after fertility-sparing treatment for glandular lesions of the uterine cervix.
     Int J Gynecol Cancer. 2024;34:216-223.
     PubMed     Abstract available
     
     
     January 2024
154. LAAN J, van Lonkhuijzen L, Hinnen K, Pieters B, et al
     Malnutrition is associated with poor survival in women receiving radiotherapy for cervical cancer.
     Int J Gynecol Cancer. 2024 Jan 17:ijgc-2023-005024.
     PubMed     Abstract available
     
     
     
155. KANG WD, Ju UC, Kim SM
     Human papillomavirus genotyping for predicting disease progression in women with biopsy-negative or cervical intraepithelial neoplasia grade 1 of low-grade intraepithelial lesion cytology.
     Int J Gynecol Cancer. 2024;34:12-18.
     PubMed     Abstract available
     
     
     
156. FITCH K, Bohn JA, Emerson JB, Boniface ER, et al
     Acceptability of human papillomavirus self-collection and the role of telehealth: a prospective, randomized study stratified by menopausal status.
     Int J Gynecol Cancer. 2024;34:19-27.
     PubMed     Abstract available
     
     
     
157. FERNANDEZ MA, Clark HD, Iniesta MD, Munsell MF, et al
     Sentinel lymph node mapping with indocyanine green using SPY-PHI in open radical hysterectomy or trachelectomy.
     Int J Gynecol Cancer. 2024;34:28-34.
     PubMed     Abstract available
     
     
     December 2023
158. RIBEIRO R, Baiocchi G, Moretti-Marques R, Linhares JC, et al
     Uterine transposition for fertility and ovarian function preservation after radiotherapy.
     Int J Gynecol Cancer. 2023;33:1837-1842.
     PubMed     Abstract available
     
     
     
159. PARPINEL G, Laas-Faron E, Balaya V, Guani B, et al
     Survival after sentinel lymph node biopsy for early cervical cancers: a systematic review and meta-analysis.
     Int J Gynecol Cancer. 2023;33:1853-1860.
     PubMed     Abstract available
     
     
     
160. PLAIKNER A, Siegler K, Kohler C
     Surgical steps of laparoscopic-assisted simple vaginal trachelectomy.
     Int J Gynecol Cancer. 2023;33:1972-1973.
     PubMed    
     
     
     November 2023
161. BORGHI C, Biagioli E, Mauro J, Roberto A, et al
     Neoadjuvant chemotherapy prior to radical hysterectomy in locally advanced cervical cancer: a systematic review and meta-analysis.
     Int J Gynecol Cancer. 2023 Nov 27:ijgc-2023-004863.
     PubMed     Abstract available
     
     
     
162. CARUSO G, Bruni S, Lapresa M, De Vitis LA, et al
     Dose-dense neoadjuvant chemotherapy before radical surgery in cervical cancer: a retrospective cohort study and systematic literature review.
     Int J Gynecol Cancer. 2023 Nov 10:ijgc-2023-004928.
     PubMed     Abstract available
     
     
     
163. PARIDA P, Baburaj G, Rao M, Lewis S, et al
     Circulating cell-free DNA as a diagnostic and prognostic marker for cervical cancer.
     Int J Gynecol Cancer. 2023 Nov 10:ijgc-2023-004873.
     PubMed     Abstract available
     
     
     
164. KOUHEN F, El Ghanmi A
     Breaking the silence: the taboo surrounding HPV vaccination in Morocco.
     Int J Gynecol Cancer. 2023;33:1835.
     PubMed    
     
     
     
165. NITECKI R, Ramirez PT, Dundr P, Nemejcova K, et al
     MILACC study: could undetected lymph node micrometastases have impacted recurrence rate in the LACC trial?
     Int J Gynecol Cancer. 2023;33:1684-1689.
     PubMed     Abstract available
     
     
     
166. ALLANSON ER, Burling M, Simcock B, Nicklin J, et al
     The Australian Society of Gynaecological Oncology Western Pacific Liaison group.
     Int J Gynecol Cancer. 2023;33:1819-1820.
     PubMed    
     
     
     October 2023
167. SALCEDO MP, Lathrop E, Osman N, Neves A, et al
     The Mulher Study: cervical cancer screening with primary HPV testing in Mozambique.
     Int J Gynecol Cancer. 2023 Oct 31:ijgc-2023-004958.
     PubMed     Abstract available
     
     
     
168. XIA L, Wang J, Wang C, Zhang Q, et al
     Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.
     Int J Gynecol Cancer. 2023 Oct 24:ijgc-2023-004705.
     PubMed     Abstract available
     
     
     
169. FRUMOVITZ M, Morani AC, Aziz A, Jhingran A, et al
     PET/CT scan improves detection of metastatic disease compared with CT scan alone in women with high-grade neuroendocrine cervical cancer: a NeCTuR study.
     Int J Gynecol Cancer. 2023 Oct 24:ijgc-2023-004907.
     PubMed     Abstract available
     
     
     
170. MBURU A, Shaffi AF
     Pathological pelvic fracture due to metastatic cervical cancer in a young immunosuppressed woman.
     Int J Gynecol Cancer. 2023 Oct 19:ijgc-2023-004479.
     PubMed    
     
     
     September 2023
171. BIZZARRI N, Russo L, Dolciami M, Zormpas-Petridis K, et al
     Radiomics systematic review in cervical cancer: gynecological oncologists' perspective.
     Int J Gynecol Cancer. 2023 Sep 15:ijgc-2023-004589.
     PubMed     Abstract available
     
     
     
172. PLAIKNER A, Siegler K, Hertel H, Jacob A, et al
     Fertility sparing therapy in women with lymph node negative cervical cancer >2cm - oncologic and fertility outcomes of neoadjuvant chemotherapy followed by radical vaginal trachelectomy.
     Int J Gynecol Cancer. 2023 Sep 11:ijgc-2023-004669.
     PubMed     Abstract available
     
     
     
173. TURCO LC, Pedone Anchora L, Scambia G, Ferrandina G, et al
     Response to: Correspondence on "Human papillomavirus independent status on pathologic response and outcomes in locally advanced cervical cancer managed with chemoradiotherapy followed by surgery" by Yuce Sari et al.
     Int J Gynecol Cancer. 2023;33:1491-1492.
     PubMed    
     
     
     
174. YUCE SARI S, Bay M, Gultekin M
     Correspondence on 'Human papillomavirus independent status on pathologic response and outcomes in locally advanced cervical cancer managed with chemoradiotherapy followed by surgery' by Turco et al.
     Int J Gynecol Cancer. 2023;33:1490.
     PubMed    
     
     
     
175. NAKISIGE C, de Fouw M, Kabukye J, Sultanov M, et al
     Artificial intelligence and visual inspection in cervical cancer screening.
     Int J Gynecol Cancer. 2023 Sep 4:ijgc-2023-004397. doi: 10.1136/ijgc-2023-004397
     PubMed     Abstract available
     
     
     
176. SALVO G, Flores Legarreta A, Ramalingam P, Jhingran A, et al
     Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study.
     Int J Gynecol Cancer. 2023;33:1359-1369.
     PubMed     Abstract available
     
     
     
177. MICHAAN N, Wenkert A, Even-Sapir E, Kerzhner K, et al
     Prognostic significance of delayed complete metabolic response on PET/CT after primary chemoradiation treatment of cervical cancer.
     Int J Gynecol Cancer. 2023 Sep 1:ijgc-2023-004703. doi: 10.1136/ijgc-2023-004703
     PubMed     Abstract available
     
     
     August 2023
178. MAURO J, Viveros-Carreno D, Vizzielli G, De Ponti E, et al
     Survival after sentinel node biopsy alone in early-stage cervical cancer: a systematic review.
     Int J Gynecol Cancer. 2023 Aug 16:ijgc-2023-004692.
     PubMed     Abstract available
     
     
     
179. GONZALEZ-OCHOA E, Milosevic M, Corr B, Abbruzzese JL, et al
     A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
     Int J Gynecol Cancer. 2023;33:1208-1214.
     PubMed     Abstract available
     
     
     July 2023
180. BOGANI G, Ghelardi A, Sopracordevole F, Annoni M, et al
     Human papillomavirus (HPV) vaccination: a call for action in Italy.
     Int J Gynecol Cancer. 2023;33:1132-1139.
     PubMed     Abstract available
     
     
     June 2023
181. OBERMAIR A, Leitao M
     Correspondence on "ESGO/ESTRO/ESP guidelines fpr the management of patients with cervical cancer: update 2023" by Cibula et al.
     Int J Gynecol Cancer. 2023 Jun 15:ijgc-2023-004645.
     PubMed    
     
     
     
182. PAREJA R, Heredia F, Leitao M
     Correspondence on 'ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023*'.
     Int J Gynecol Cancer. 2023 Jun 9:ijgc-2023-004656. doi: 10.1136/ijgc-2023-004656
     PubMed    
     
     
     
183. KOBAYASHI E, Takekuma M, Enomoto T, Okamoto A, et al
     Response to: Commentary on "Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081S-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081" by Ramirez et al.
     Int J Gynecol Cancer. 2023;33:1012.
     PubMed    
     
     
     
184. CORDOBA A, El Hajj H, Martinez-Gomez C, Hudry D, et al
     Should the cut-off for concomitant radiochemotherapy and intracavitary 3D adaptive uterovaginal brachytherapy be 3 cm?
     Int J Gynecol Cancer. 2023;33:1010-1011.
     PubMed    
     
     
     
185. CASTILLO MH, Rodriguez R, Chavez C, Baltazar D, et al
     Control and management of gynecological cancer in Peru.
     Int J Gynecol Cancer. 2023;33:995-996.
     PubMed    
     
     
     
186. NGUYEN CGT, Phillips S, Chen A, Harrison R, et al
     Isolated tumor cells in a patient with early-stage cervical cancer.
     Int J Gynecol Cancer. 2023 Jun 2:ijgc-2022-004115. doi: 10.1136/ijgc-2022-004115
     PubMed    
     
     
     May 2023
187. CHARGARI C, Tanderup K, Planchamp F, Chiva L, et al
     ESGO/ESTRO quality indicators for radiation therapy of cervical cancer.
     Int J Gynecol Cancer. 2023 May 31:ijgc-2022-004180.
     PubMed     Abstract available
     
     
     
188. ZHANG X, Wang Y, Lv X, Wang F, et al
     Intratumoral injection of oncolytic virus (H101) in combination with concurrent chemoradiotherapy for locally advanced cervical cancer.
     Int J Gynecol Cancer. 2023 May 19:ijgc-2022-003914.
     PubMed     Abstract available
     
     
     
189. VIVEROS-CARRENO D, Vieira-Serna S, Grillo-Ardila CF, Rodriguez J, et al
     Definitive pelvic radiotherapy for patients with newly diagnosed stage IVB cervical cancer: a systematic review.
     Int J Gynecol Cancer. 2023 May 16:ijgc-2023-004465.
     PubMed     Abstract available
     
     
     
190. CIBULA D, Raspollini MR, Planchamp F, Centeno C, et al
     ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023.
     Int J Gynecol Cancer. 2023;33:649-666.
     PubMed     Abstract available
     
     
     
191. ISHIKAWA M, Shibata T, Kataoka T, Takekuma M, et al
     Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinom
     Int J Gynecol Cancer. 2023;33:692-700.
     PubMed     Abstract available
     
     
     
192. PELEG HASSON S, Felder S, Helpman L, Taylor A, et al
     Outcomes associated with treatment to all sites of disease in patients with stage IVB cancer of the cervix.
     Int J Gynecol Cancer. 2023;33:683-691.
     PubMed     Abstract available
     
     
     
193. CUSCHIERI K, Fellner MD, Arroyo Muhr LS, Padalko E, et al
     Quality assurance in human papillomavirus testing for primary cervical screening.
     Int J Gynecol Cancer. 2023;33:802-811.
     PubMed     Abstract available
     
     
     
194. LEVYTSKA K, Pena SR, Brown J, Yu Z, et al
     Opioid and benzodiazepine use in gynecologic oncology patients.
     Int J Gynecol Cancer. 2023;33:786-791.
     PubMed     Abstract available
     
     
     April 2023
195. BUDA A, Fanfani F
     The patterns of growth of cervical cancer: a challenge to personalized radical surgery.
     Int J Gynecol Cancer. 2023 Apr 25:ijgc-2023-004556.
     PubMed    
     
     
     
196. RAMIREZ PT
     ESGO/ESTRO/ESP updated guidelines in cervical cancer.
     Int J Gynecol Cancer. 2023 Apr 13:ijgc-2023-004523.
     PubMed    
     
     
     
197. SAGAE S, Toita T, Matsuura M, Saito M, et al
     Improvement in radiation techniques for locally advanced cervical cancer during the last two decades.
     Int J Gynecol Cancer. 2023 Apr 11:ijgc-2022-004230.
     PubMed     Abstract available
     
     
     
198. TOUHAMI O, Plante M, St-Gelais J, Frumovitz M, et al
     Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix.
     Int J Gynecol Cancer. 2023;33:623-627.
     PubMed    
     
     
     
199. KESIC V, Carcopino X, Preti M, Vieira-Baptista P, et al
     The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus s
     Int J Gynecol Cancer. 2023;33:446-461.
     PubMed     Abstract available
     
     
     
200. KAMANI MO, Kyrgiou M, Joura E, Zapardiel I, et al
     ESGO Prevention Committee opinion: is a single dose of HPV vaccine good enough?
     Int J Gynecol Cancer. 2023;33:462-464.
     PubMed    
     
     
     
201. GOMEZ CHEREY JF, Payalef SN, Fleider L, Reyes AP, et al
     Microbiota unbalance in relation to high-risk human papillomavirus cervical infection.
     Int J Gynecol Cancer. 2023;33:482-488.
     PubMed     Abstract available
     
     
     
202. BOCCIOLONE L, Candotti G, Cioffi R, Rabaiotti E, et al
     Sentinel lymph node biopsy in open surgery for gynecological malignancies.
     Int J Gynecol Cancer. 2023;33:636-637.
     PubMed    
     
     
     March 2023
203. SOOCHIT A, Zhang C, Feng Y, Luo X, et al
     Impact of different post-operative treatment modalities on long-term outcomes in International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIICp cervical cancer.
     Int J Gynecol Cancer. 2023 Mar 31:ijgc-2022-004234.
     PubMed     Abstract available
     
     
     
204. CAPOZZI VA, Rotondella I, De Finis A, Scarpelli E, et al
     Rectovaginal fistula repair by Martius flap after exclusive chemoradiation in a patient with advanced cervical cancer.
     Int J Gynecol Cancer. 2023 Mar 23:ijgc-2023-004365.
     PubMed    
     
     
     
205. OBERMAIR A, Pareja R
     Can simple hysterectomy replace radical hysterectomy as treatment of early-stage cervical cancer?
     Int J Gynecol Cancer. 2023 Mar 10:ijgc-2023-004372.
     PubMed    
     
     
     
206. VIVEROS-CARRENO D, Fernandes A, Pareja R
     Updates on cervical cancer prevention.
     Int J Gynecol Cancer. 2023;33:394-402.
     PubMed     Abstract available
     
     
     
207. GRAU JF, Farinas-Madrid L, Garcia-Duran C, Garcia-Illescas D, et al
     Advances in immunotherapy in cervical cancer.
     Int J Gynecol Cancer. 2023;33:403-413.
     PubMed     Abstract available
     
     
     
208. CHELARIU-RAICU A, Mahner S, Moore KN, Lorusso D, et al
     Integrating antibody drug conjugates in the management of gynecologic cancers.
     Int J Gynecol Cancer. 2023;33:420-429.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge.